Canada’s regulatory agency approved Samsung Bioepis’ Byooviz as the first ranibizumab biosimilar for the Canadian market for the treatment of ophthalmic conditions.
Health Canada has approved Byooviz, a biosimilar referencing Lucentis (ranibizumab), for the treatment for several ophthalmic conditions. Byooviz represents the first ranibizumab biosimilar to be approved for the Canadian market.
The biosimilar was developed through a commercialization agreement between Samsung Bioepis and Biogen Canada and is indicated for the treatment of:
“We are pleased to have achieved a key milestone with Health Canada’s regulatory approval of our ranibizumab biosimilar….The approval is part of our commitment to providing a treatment option for patients with retinal vascular disorders in Canada,” said Byoungin Jung, vice president and regulatory affairs team leader at Samsung Bioepis, a company statement.
The news comes just over a month after Health Canada approved Ontruzant, a trastuzumab biosimilar referencing Herceptin, also developed by Samsung Bioepis.
Byooviz is the sixth biosimilar developed by Samsung Bioepis to be approved in Canada, following Ontruzant, Brenzys (etanercept) in August 2016, Renflexis (infliximab) in December 2017, Hadlima (adalimumab) in May 2018, and Aybintio (bevacizumab) in November 2021. Brenzys references Enbrel, Renflexis references Rituxan, Hadlima and Simlandi are biosimilars for Humira, and Aybintio references Avastin.
Byooviz was also the first biosimilar for Biogen to receive approval in Canada.
Ranibizumab is an anti-vascular endothelial growth factor therapy for ophthalmic conditions related to the retina, such as AMD, which impacts nearly 2 million people in Canada and accounts for 90% of new cases of legal blindness in the country.
“With an estimated eight million Canadians at risk of losing their sight due to an eye disease and AMD the leading cause of vision loss in those over 50, we are excited to be part of this important milestone in providing new treatment options for those affected by debilitating ophthalmic diseases like retinal vascular disorders…. We believe biosimilars are a key step towards providing more Canadians with access to quality treatment, while offering significant savings to our healthcare system,” said Eric Tse, general manager at Biogen Canada.
The approval was based on nonclinical data and data from randomized, double-masked, parallel group, multicenter phase 3 study that demonstrated comparable efficacy, safety, pharmacokinetics, and immunogenicity of the biosimilar with the reference product in patients with wet AMD.
Previously, Byooviz became the first FDA-approved ophthalmology biosimilar in September 2021 and was approved in August 2021 for marketing authorization in the European Union and the United Kingdom.
In November 2019, Samsung Bioepis and Biogen entered into a commercialization agreement for 2 ophthalmology biosimilars, including Byooviz (SB11) and SB15, an aflibercept biosimilar referencing Eylea. As part of the agreement, Samsung Bioepis oversees the manufacturing and development of the biosimilars and Biogen is in charge of commercialization in the United States, Canada, the European Union, the United Kingdom, Japan, and Australia.
In January 2022, Biogen sold its full ownership stake in Samsung Bioepis for $2.3 billion after it increased it from 15% to 50% in 2012. Under the agreement, Biogen received $1 billion in cash at closing, an $812.5 million payment at the first anniversary of the transaction close, and a $437.5 million at the second anniversary. Biogen is also eligible to receive up to $50 million upon achievement of certain commercial milestones.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.